Skip to main content
. 2019 Dec 4;39(12):BSR20192452. doi: 10.1042/BSR20192452

Table 1. Basic information of the studies included in the meta-analysis.

First author Year Country Race Cases Cancer type Control Control source Genotyping assay
CC CT TT CC CT TT
Al-Qadoori 2019 Iraq Asian 37 23 2 Bladder cancer 31 7 0 PB Gene sequencing
An 2007 U.S.A. Caucasian 445 293 91 HNSCC 454 342 58 HB PCR-RFLP
Bai 2007 China Asian 184 193 48 LAC 446 456 88 HB TaqMan
China Asian 149 149 34 LSCC 446 456 88 HB TaqMan
China Asian 31 25 8 SCLC 446 456 88 HB TaqMan
Broberg 2005 Sweden Caucasian 35 20 6 Bladder cancer 92 55 8 PB MassARRAY
Chen 2013 China Asian 45 60 26 Cervical cancer 101 118 38 HB PCR-RFLP
de Verdier 2010 Sweden Caucasian 138 138 35 Bladder cancer 196 124 10 PB PCR-RFLP
Doherty 2011 U.S.A. Mixed 411 257 49 Endometrial cancer 384 278 61 PB PCR-RFLP/SNaPshot
Dong 2008 China Asian 141 90 22 GCA 272 282 58 PB PCR-RFLP
Farnebo 2015 Sweden Caucasian 89 63 17 HNSCC 219 105 20 PB PCR-RFLP
Figl 2010 Spain/Germany Caucasian 626 477 81 Melanoma 670 516 88 PB TaqMan
Garcia 2006 Spain Caucasian 583 440 85 Bladder cancer 599 435 75 HB SNP500Cancer
Guo 2008 China Asian 156 133 38 ESCC 272 282 58 PB PCR-RFLP
He 2016 China Asian 201 198 51 Breast cancer 228 174 28 PB MassARRAY
He 2012 China Asian 104 90 16 Pancreatic cancer 106 85 22 PB SNaPshot
Hu 2005 China Asian 124 171 25 Lung cancer 158 145 19 PB PCR-PIRA
Hua 2016a China Asian 432 531 178 CRC 429 583 161 PB TaqMan
Hua 2016b China Asian 457 524 161 Gastric cancer 429 583 161 PB TaqMan
Huang 2006 U.S.A. Mixed 397 261 31 CRC 403 259 41 HB SNP500Cancer
Ibarrola 2011 Spain Caucasian 323 227 49 Melanoma 198 158 23 PB/HB MassARRAY
Jiao 2011 China Asian 127 177 30 GBC 163 146 20 HB PCR-RFLP
Jorgensen 2007 U.S.A. Caucasian 153 87 13 Breast cancer 157 104 14 PB TaqMan
Kim 2002 Korea Asian 104 102 12 Lung cancer 77 62 10 PB PCR-RFLP
Lee 2005 Korea Asian 113 84 13 LSCC 223 179 29 PB PCR-RFLP
Korea Asian 79 58 4 LAC 223 179 29 PB PCR-RFLP
Korea Asian 39 28 6 SCLC 223 179 29 PB PCR-RFLP
Li 2006 U.S.A. Caucasian 338 214 50 Melanoma 318 248 37 HB PCR-RFLP
Li 2014 China Asian 92 91 19 Gastric cancer 144 153 30 PB PCR-RFLP
Li 2010 China Asian 163 248 89 HCC 169 250 88 HB TaqMan
Liang 2018 China Asian 98 89 18 Pancreatic cancer 116 90 24 HB SNaPshot
Liu 2016 China Asian 444 351 96 Gastric cancer 424 408 95 HB MassARRAY
Liu 2012 China Asian 242 294 64 Bladder cancer 272 285 52 PB PCR-RFLP
Liu 2019 China Asian 178 159 54 Uterine leiomyoma 183 232 78 PB Sequence Detection System
Long 2010 China Asian 170 156 35 GAA 280 274 62 HB TaqMan
McWilliams 2008 U.S.A. Mixed 246 182 29 Pancreatic cancer 339 211 32 HB SNPstream or Pyrosequencing
Monroy 2011 U.S.A. Mixed 92 90 8 HL 137 71 10 PB MassARRAY
Na 2012 China Asian 213 124 23 Breast cancer 228 118 14 HB MassARRAY
Nigam 2019 China Asian 22 22 26 Oral cancer 69 145 83 PB PCR-RFLP
Ozgoz 2019 Turkey Caucasian 57 38 7 Breast cancer 67 26 7 PB MassARRAY
Pan 2009 U.S.A Caucasian 228 129 26 Esophageal cancer 251 178 21 PB TaqMan
Paszkowska 2015 Poland Caucasian 443 269 41 CRC 548 563 177 PB MassARRAY/Taqman
Paszkowska 2013 Poland Caucasian 245 240 34 Melanoma 548 563 177 PB MassARRAY
Perez 2013 U.S.A. Caucasian 0 63 115 Breast cancer 21 131 203 PB TaqMan
Ravegnini 2016 Italy Caucasian 42 34 5 GIST 90 45 12 PB TaqMan
Roberts 2011 U.S.A. Mixed 167 100 18 Breast cancer1 317 193 40 PB MassARRAY
U.S.A. Mixed 437 273 48 Breast cancer2 793 478 72 PB MassARRAY
Sak 2006 U.K. Mixed 279 202 57 Bladder cancer 317 210 38 PB/HB TaqMan
Sakoda 2012 U.S.A. Caucasian 401 299 43 Lung cancer 822 566 87 PB GoldenGate/Taqman
Sankhwar 2016 India Asian 52 113 69 Bladder cancer 87 112 59 PB PCR-RFLP/gene sequencing
Santos 2013 Portugal Caucasian 47 55 4 Thyroid cancer 95 98 19 HB PCR-RFLP
Shen 2006 U.S.A. Caucasian 96 50 9 Breast cancer 91 55 5 PB TaqMan
Shen 2008 U.S.A. Mixed 614 385 62 Breast cancer 632 417 56 PB Fluorescence polarization
Shen 2005 China Asian 56 47 13 Lung cancer 50 47 13 PB TaqMan
Slyskova 2012 Czech Republic Caucasian 36 24 9 CRC 37 24 3 PB PCR-RFLP
Smith 2008 U.S.A. Caucasian 178 116 23 Breast cancer 211 161 29 PB MassARRAY
U.S.A. Others 44 7 1 Breast cancer 61 14 0 PB MassARRAY
Steck 2014 U.S.A. Others 175 51 2 CRC 276 47 0 PB MassARRAY
U.S.A. Caucasian 177 104 22 CRC 293 207 35 PB MassARRAY
Tang 2011 China Asian 40 55 14 ALL 80 74 15 PB MassARRAY
Weiss 2005 U.S.A. Mixed 211 129 31 Endometrial cancer 213 166 41 PB SNaPshot
Wu 2011a China Asian 172 195 52 CRC 315 406 117 PB PCR-RFLP
Wu 2011b China Asian 65 86 22 Breast cancer 69 85 16 PB PCR-RFLP
Yang 2012 China Asian 197 322 99 Breast cancer 235 312 75 PB PCR-RFLP
Yang 2008 China Asian 52 73 28 NPC 76 79 13 PB PCR-RFLP
Zhao 2018 China Asian 46 35 8 Ovarian cancer 127 175 54 PB TaqMan
Zheng 2016 China Asian 111 108 34 Neuroblastoma 205 250 76 PB TaqMan
Zhou 2008 China Asian 103 78 27 Ovarian cancer 118 95 18 PB PCR-RFLP
Zhu 2018 China Asian 64 59 22 Nneuroblastoma 205 250 76 PB TaqMan
Zhu 2008 China Asian 110 60 18 ESCC 83 88 32 PB PCR-RFLP
Zhu 2007 U.S.A. Caucasian 323 193 30 Bladder cancer 310 215 24 HB TaqMan

Abbreviations: ALL, acute lymphoblastic leukemia; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GAA, gastric antrum adenocarcinoma; GBC, primary gallbladder adenocarcinoma; GCA, gastric cardiac adenocarcinoma; GIST, gastrointestinal stromal tumour; HB, hospital-based; HCC, hepatocellular carcinoma; HL, Hodgkin lymphoma; HNSCC, head and neck squamous cell carcinoma; LAC, lung adenocarcinoma; LSCC, lung squamous cell carcinoma; NPC, nasopharyngeal cancer; PB, population-based; PCR, polymerase chain reaction; PIRA, primer-introduced restriction analysis; RFLP, restriction fragment length polymorphism; SCLC, Small cell lung carcinoma; SNP, single nucleotide polymorphism.

1 Premenopausal.

2 Postmenopausal.